This retrospective case series involved a review of medical records at a single tertiary care center. Charbel Issa and ...

Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi ...

projected on-label aflibercept 2 mg Q8W; 70% of patients required 0-1 supplemental injection and 57% were injection-free ... the basis of a BLA submission for 4D-150 in DME, based on review of data ...

projected on-label aflibercept 2 mg Q8W; 70% of patients required 0-1 supplemental injection and 57% were ... submission for 4D-150 in DME, based on review of data from SPECTRA and PRISM (wet ...

The FDA granted regenerative medicine advanced therapy designation to 4D-150 for the treatment of diabetic macular edema, according to a press release from 4D Molecular Therapeutics.

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expect ...

Faricimab demonstrated “rapid improvements” in anatomic features across previously treated and treatment-naïve patients, ...